Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company located in Cambridge, Massachusetts, that is pioneering solutions for the urgent challenge of multidrug-resistant (MDR) bacterial infections and rare diseases. With a strong emphasis on innovation, Spero is advancing a robust pipeline of novel therapeutics designed to improve patient outcomes in areas with significant unmet medical needs. The company's strategic focus on combating resistance in bacterial pathogens positions it as a key player in addressing critical healthcare challenges in the United States and beyond. Show more

Location: 675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA, UNITED STATES, 02139, Cambridge, MA, 02139, USA | Website: https://sperotherapeutics.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

123.4M

52 Wk Range

$0.51 - $3.22

Previous Close

$2.19

Open

$2.15

Volume

277,114

Day Range

$2.14 - $2.26

Enterprise Value

78.12M

Cash

48.62M

Avg Qtr Burn

N/A

Insider Ownership

22.93%

Institutional Own.

16.38%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Tebipenem HBr (previously SPR994): oral carbapenem Details Bacterial infection, Urinary tract infection	NDA Acceptance for review	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SPR720 Details Bacterial infection, Lung disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.